Tetraphase Pharmaceuticals   Report issue

Contributed to NME For profit Phase 1 Phase 3
Founded: Watertown MA United States (2006)
Status: Acquired by Melinta Therapeutics (2020)

Organization Overview

First Clinical Trial
2011
NCT01265784
First Marketed Drug
2018
eravacycline (Xerava)
First NDA Approval
2018
eravacycline (Xerava)
Last Known Activity
2018

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Davia Clinical Research | Tetraphase Pharmaceuticals | Tetraphase Pharmaceuticals, Inc. | TETRAPHASE PHARMS

Active Ingredients

Marketed Drugs (1)

eravacycline (Xerava) (2018 NDA)

Drugs in Phase 3 Trials (4)

eravacycline (Xerava) (10 trials)

ertapenem (invanz) (3 trials)

levofloxacin (levaquin) (2 trials)

meropenem (merrem) (1 trial)

Drugs in Phase 1 Trials (3)

moxifloxacin (avelox) (1 trial)

tp-271 (4 trials)

tp-6076 (1 trial)

Indications

Approved Indications


 

Intraabdominal Infections

Experimental Indications (Clinical Trials, Phases 1-4)


 

Appendicitis (Phase 3)

Bacterial Infections (Phase 1)

Communicable Diseases (Phase 3)

Infections (Phase 3)

Intraabdominal Infections (Phase 3)

Kidney Diseases (Phase 1)

Kidney Failure, Chronic (Phase 1)

Pneumonia (Phase 1)

Urinary Tract Infections (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 15
  • # of Trial APIs: 7